Syncom Formulations (India) Limited (NSE:SYNCOMF)

Market Cap	12.83B -19.9%
Revenue (ttm)	5.03B +28.6%
Net Income	689.58M +76.2%
EPS	0.70 +75.0%
Shares Out	n/a
PE Ratio	18.61
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,883,376
Average Volume	1,944,937
Open	13.56
Previous Close	13.80
Day's Range	13.36 - 14.18
52-Week Range	10.21 - 23.49
Beta	0.76
RSI	52.02
Earnings Date	May 22, 2026

About NSE:SYNCOMF

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 744
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SYNCOMF

Financial Performance

In fiscal year 2025, NSE:SYNCOMF's revenue was 4.65 billion, an increase of 76.55% compared to the previous year's 2.63 billion. Earnings were 494.35 million, an increase of 95.28%.